Hepatic Pharmacokinetics and Pharmacodynamics With Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir Treatment and Variable Ribavirin Dosage-Reference-Cited by-同舟云学术

Hepatic Pharmacokinetics and Pharmacodynamics With Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir Treatment and Variable Ribavirin Dosage

Published:2017-09-27 Issue:3 Volume:217 Page:474-482
ISSN:0022-1899
Container-title:The Journal of Infectious Diseases
language:en
Short-container-title:

Author:

Talal Andrew H¹,Dumas Emily O²,Bauer Barbara¹,Rejman Richard M¹,Ocque Andrew¹,Morse Gene D¹,Lucic Danijela³,Cloherty Gavin A³,King Jennifer⁴,Zha Jiuhong²,Zhang Hongtao²,Cohen Daniel E²,Shulman Nancy²,Pawlotsky Jean-Michel⁵⁶,Hézode Christophe⁶⁷

Affiliation:

1. University at Buffalo, Buffalo, NY

2. AbbVie Inc, North Chicago, IL

3. Abbott Diagnostics, Abbott Park, IL

4. Roivant Sciences Inc, Durham, NC

5. National Reference Center for Viral Hepatitis B, C and D, Department of Virology, Hôpital Henri Mondor, Université Paris-Est

6. INSERM U955

7. Department of Hepatology, Hôpital Henri Mondor, Université Paris-Est, Créteil, France

Funder

AbbVie

Abbott Laboratories

Troup Fund of the Kaleida Health Foundation

National Center for Advancing Translational Sciences

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Immunology and Allergy

Link

http://academic.oup.com/jid/article-pdf/217/3/474/24262984/jix495.pdf

Reference35 articles.

1. Impact of all oral anti-hepatitis C virus therapy: A meta-analysis;Bansal;World J Hepatol,2015

2. Hepatitis C virus infection;Lauer;N Engl J Med,2001

3. Hepatitis C;Webster;Lancet,2015

4. Antiviral action of ribavirin in chronic hepatitis C;Pawlotsky;Gastroenterology,2004

5. Prevalence and impact of baseline NSA resistance associated variants (RAVs) on the efficacy of elbasvir/grazoprevir (EBR/GZR) against GT1a infection;Jacobson;Hepatology,2015

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. HCV Antiviral Drugs Have the Potential to Adversely Perturb the Fetal-Maternal Communication Axis through Inhibition of CYP3A7 DHEA-S Oxidation;Drug Metabolism and Disposition;2024-01-24

2. Simultaneous Estimation of Ombitasvir, Paritaprevir and Ritonavir in Tablet Dosage Form by Reverse Phase High-Performance Liquid Chromatography;International Journal of Life Science and Pharma Research;2022-07-15

3. Chemometry‐assisted UV‐spectrophotmetric methods for the simultaneous determination of paritaprevir, ritonavir, and ombitasvir in their combined tablet dosage forms: A comparative study;Journal of Chemometrics;2021-02-25

4. Intrahepatic Viral Kinetics During Direct-Acting Antivirals for Hepatitis C in Human Immunodeficiency Virus Coinfection: The AIDS Clinical Trials Group A5335S Substudy;The Journal of Infectious Diseases;2020-03-23

5. Fine‐Needle Aspiration for the Evaluation of Hepatic Pharmacokinetics of Vaniprevir: A Randomized Trial in Patients With Hepatitis C Virus Infection;Clinical Pharmacology & Therapeutics;2020-02-08